retatrutide phase 2 trial weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Trial Data Dosing Schedule :

The branded formulation Ozempic recently also became FDA approved to reduce the risks of major cardiovascular outcomes in adults with type 2 diabetes mellitus with known heart disease, and to reduce the risk of kidney damage and cardiovascular related deaths in adults with type 2 diabetes mellitus and chronic kidney disease (CKD).It works by enhancing insulin release, reducing glucagon production, and slowing stomach emptying, which can reduce appetite, increase feelings of fullness, and encourage weight loss

Lily, who asked to be identified by only her first name because she is not out to her family as transgender, has tried other medications since then, and previously tried lifestyle programs to control her weight

The surgical technique is based on your anatomy, not the medication itself

Efficient delivery of GLP-1, which can aid in weight management and blood sugar control

Weight loss is a struggle for millions of people across the world from all walks of life